Home > Insider Trading > Filing (0001144204-12-026347)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1006281	Protalix Biotherapeutics Inc.	PLX	Biological Products, (No Disgnostic Substances) (2836)	650643773

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1385112	David Aviezer	C/O Protalix Biotherapeutics, Inc. 2 Snunit St, Science Park, Pob 455 Carmiel L3 20100	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-05-02	326,267	$0.12	326,267	No	4	M	Indirect	By Trust
Common Stock	Acquisiton	2012-05-02	123,733	$0.97	450,000	No	4	M	Indirect	By Trust
Common Stock	Disposition	2012-05-02	450,000	$7.13	0	No	4	S	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	By Trust
No	4	M	Indirect	By Trust
No	4	S	Indirect	By Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2012-05-02	326,267	$0.00	326,267	$0.12
Common Stock	Stock Options (Right to Buy)	Disposition	2012-05-02	123,733	$0.00	123,733	$0.97

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2013-12-08	No	4	M	Direct
853,563		2016-09-10	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
All of the options listed in Table II have vested.
Does not include (i) options to purchase 600,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018, (ii) options to purchase 100,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019, and (iii) options to purchase 250,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.